Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03302403
Other study ID # CGZ001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date December 29, 2017
Est. completion date December 12, 2023

Study information

Verified date October 2020
Source First Affiliated Hospital of Wenzhou Medical University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A single arm, open-label pilot study is designed to determine the safety, efficacy and cytokinetics of CAR T cells in patients with malignant tumors with positive antigen targets.

CAR T cells are genetically engineered to express single-chain variable fragment (scFv) targeting indication-specific antigens.

The investigational CAR T cells and proposed indications are as follows:

CAR-CD19 T cells for B cell leukaemia/lymphoma; CAR-BCMA T cells for myeloma; CAR-GPC3 T cell for hepatocellular carcinoma; CAR-CLD18 T cells for pancreatic carcinoma and adenocarcinoma of esophagogastric junction.


Description:

This study is designed to determine the safety, tolerability and engraftment potential of lentivirus-transduced CAR T cells in patients with malignant tumors.

Primary objectives:

1. Determine the safety and tolerability of CAR T cells (autologous T cells transduced with chimeric antigen receptors recognizing CD19, BCMA, GPC3 and Claudin18.2) in patients with malignant tumors (B-cell lymphoblastic leukaemia/lymphoma, myeloma, hepatocellular carcinoma, pancreatic carcinoma and adenocarcinoma of esophagogastric junction).

2. Observe the cytokinetics of CAR T cells.

Secondary objectives:

1. Observe the efficacy of CAR T cells in patients with malignant tumors.

2. Make an evaluation on the distribution and in vivo survival of CAR T cells in targeted tissues.

3. Observe the immunogenicity of CAR T cells, and determine if there are anti-scFv cellular immune response and anti-scFv humoral immune response.

4. Observe the changes of cell subsets for CAR T cells against T cells (Tcm, central memory T lymphocytes; Tem, effector memory T lymphocytes; Treg, regulatory T-lymphocytes).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 18
Est. completion date December 12, 2023
Est. primary completion date December 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

I. B-Cell Lymphoblastic Leukaemia/Lymphoma

1. Patients aged between 18 ~ 65 with B-cell lymphoblastic leukaemia/lymphoma.

2. CD19-positive B-cell lymphoblastic leukaemia/lymphoma.

3. Patients with unmet medical needs for which there are no effective therapies known at this time:

A. Relapsed or Refractory (r/r) Acute Lymphoblastic Leukemia (ALL)

Patients with r/r ALL for whom hematopoietic stem cell transplantation (HSCT) is not suitable due to following reasons:

1. Age;

2. Excessive tumor burden or concomitant disease;

3. No donor available.

B. CD19-positive Follicular Lymphoma:

1. At least 2 prior chemotherapy regimens (not including single agent monoclonal antibody (Rituxan) therapy;

2. Less than 6 months between last chemotherapy and disease progression (most recent progression free interval < 6 months);

3. Disease progression after most recent systemic therapy (chemotherapy, MoAb, etc.).

C. Chronic Lymphocytic Leukemia (CLL)

1. At least 2 prior chemotherapy regimens (not including single agent monoclonal antibody (Rituxan) therapy);

2. Less than6 months between last chemotherapy and disease progression (most recent progression free interval < 6 months);

3. Not eligible or appropriate for conventional HSCT.

4. Disease progression after most recent systemic therapy (chemotherapy, MoAb, etc.).

D. Mantle Cell Lymphoma

1. At least 2 prior chemotherapy regimens (not including single agent monoclonal antibody (Rituxan) therapy);

2. Disease progression after most recent systemic therapy (chemotherapy, MoAb, etc.);

3. Relapsed after prior autologous SCT.

E. B-Cell Prolymphocytic Leukemia (PLL)

Relapsed or residual disease after at least 1 prior therapy and not eligible for HSCT.

F. CD19-positive Diffuse Large B Cell Lymphoma

1. At least 2 prior chemotherapy regimens (not including single agent monoclonal antibody (Rituxan) therapy;

2. Stage III-IV disease.

3. Less than 6 months between last chemotherapy and disease progression (most recent progression free interval < 6 months);

4. Disease progression after most recent therapy (chemotherapy, MoAb, etc.).

4. Expected survival > 12 weeks.

5. At least one measurable lesion (= 10 mm) for patients with lymphoma.

6. ECOG scores 0-1, or KPS scores > 70.

7. Adequate venous access for apheresis or venous sampling, and no other contraindications for leukapheresis.

8. WBC = 2.5×10^9/L; PLT = 60×10^9/L (for patients with lymphoma); Hb = 9.0 g/dL; LY = 0.47×10^9/L; LY% = 15%.

9. Serum Alb = 30 g/L.

10. Serum creatinine = 1.5 ULN.

11. ALT = 2.5 ULN; AST = 2.5 ULN.

12. Serum total bilirubin = 1.5 ULN. The above lab results should not include those obtained from continuous supportive treatment that is ongoing.

II. Myeloma

1. Patients aged between 18 ~ 75 with relapsed or refractory multiple myeloma.

2. Bone marrow sample is confirmed as BCMA-positive by flow cytometry or pathological examination.

3. Patients with relapsed or refractory malignancies who meet the following descriptions:

1. Curative efficacy is little or disease progressed after 2 courses of standard treatment regimen;

2. Disease relapsed after chemotherapy or HSCT. Curative efficacy is little or disease progressed after 2 courses of original treatment regimen;

3. More than 30 days between last treatment and disease progression;

4. There is no indication for HSCT at present;

5. Disease progression is defined as per "Chinese Guidelines for Diagnosis and Treatment of Multiple Myeloma (Version 2015)". One or more of the following conditions should be met:

i. Serum M-protein increases = 25% (absolute increase should be = 5 g/L). If serum M protein is = 50 g/L at baseline, increase of serum M protein can be = 10 g/L; ii. Urine M-protein increases = 25% (absolute increase should be = 200 mg/24 h); iii. If the serum and urine M-protein are not detectable, a = 25% increase in the difference between involved and uninvolved FLC levels is required (absolute increase should be = 100 mg/L); iv. Bone marrow plasma cell percentage increases = 25% (absolute increase should be = 10%); v. Size of existing bone lesions or soft tissue plasmacytomas increased by = 25%, or development of new lytic bone lesions or oft tissue plasmacytomas; vi. Development of hypercalcemia that can be attributed to plasma cell proliferative disorder (corrected calcium is > 2.8 mmol/L or 11.5 mg/dL).

4. Expected survival > 12 weeks.

5. Disease is measurable, and at least one of the following conditions should be satisfied:

1. Serum M-protein is = 10 g/L;

2. 24-hour urine M-protein is = 200 mg;

3. Serum FLC is = 5 mg/dL;

4. Plasmacytomas that can be measured or evaluated by imaging;

5. Bone marrow plasma cell percentage is = 20%.

6. ECOG scores 0 - 1 or CCI scores = 2.

7. Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.

8. WBC = 1.5×10^9/L; PLT = 45×10^9/L; Hb = 9.0 g/dL.

9. Serum creatinine = 1.5 ULN.

10. ALT = 2.5 ULN; AST = 2.5 ULN. The above lab results should not include those obtained from continuous supportive treatment that is ongoing.

III. Hepatocellular Carcinoma (HCC)

1. Patients aged 18 ~ 70 with refractory hepatocellular carcinoma.

2. Patients with HCC that cannot be eradicated by resection who have received ablation or resection in the last 4 to 12 weeks.

3. IHC testing confirmed as GPC3-positive HCC.

4. Expected survival > 12 weeks.

5. At least one measurable lesion (= 10 mm).

6. Cirrhosis of the liver: Child-Pugh Class A, or Child-Pugh Class B scored at 7.

7. ECOG scores 0 - 1 or KPS scores > 70.

8. Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.

9. Hematology:

WBC = 2.5×10^9/L; PLT = 60×10^9/L; Hb = 9.0 g/dL; MID = 1.0×10^9/L; LY = 0.4×10^9/L.

10. Blood Chemistry:

Serum Alb = 30 g/L; Serum lipase and serum amylase < 1.5 ULN; Serum creatinine = 1.5 ULN; ALT = 5 ULN; AST = 5 ULN; Serum total bilirubin = 2.5 ULN.

11. Coagulation Test:

Prothrombin time is at most 4 seconds longer than normal value.

12. Able to understand and sign the informed consent. All test results should be within their normal ranges, and patients are not receiving continuous supportive treatment.

IV. Pancreatic Carcinoma and Adenocarcinoma of Esophagogastric Junction

1. Patients aged 18 ~ 70 with pathologically confirmed advanced pancreatic carcinoma and adenocarcinoma of esophagogastric junction.

2. IHC testing confirmed as Claudin18.2 positive.

3. Patients with advanced pancreatic carcinoma and adenocarcinoma of esophagogastric junction that cannot be eradicated by resection.

4. Expected survival after first dose of study drug > 12 weeks.

5. At least one measurable lesion (= 10 mm) available for imaging assessment.

6. ECOG scores 0 - 1.

7. Adequate venous access for apheresis and venous blood sampling, and no other contraindications for leukapheresis.

8. WBC = 2.5×10^9/L; PLT = 100×10^9/L; Hb = 9.0 g/dL; MID = 1.5×10^9/L; LY = 0.47×10^9/L; LY% = 15%.

9. Serum Alb = 30 g/L.

10. Serum lipase and serum amylase < 1.5 ULN.

11. Serum creatinine = 1.5 ULN.

12. ALT = 2.5 ULN; AST = 2.5 ULN; If osseous metastasis or liver metastasis is developed and alkaline phosphatase is > 2.5 ULN, than ALT and AST should be < 1.5 ULN.

13. Serum total bilirubin = 1.5 ULN.

14. PT: INR < 1.7; PT < (ULN + 4) s All test results should be within their normal ranges, and patients are not receiving continuous supportive treatment.

Exclusion Criteria:

Patients with any of the following conditions are not eligible for this study.

1. Transduction of target lymphocytes < 10%, expansion in response to aCD3/CD28 costimulation < 5-fold.

2. Pregnant or lactating women.

3. HIV positive, or HCV positive

4. Uncontrolled active infection, including active tuberculosis and HBV DNA copies = 1×10^3 copies/mL.

5. Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.

6. Allergic to immunotherapies and related drugs.

7. Patients with heart disease for which treatment is needed or with poorly controlled hypertension.

8. Hyponatremia: serum sodium level < 125 mmol/L.

9. Baseline serum potassium < 3.5 mmol/L (taking potassium supplements before participating in the study to raise potassium level is acceptable).

10. Previous treatment with chemoradiotherapy, immunotherapy and tumor-targeting drug conducted 2 weeks prior to participation in this study or blood collection.

11. Patients have undertaken immunosuppressor for graft-versus-host disease (GVHD) within 4 weeks before participation in this study or blood collection, or the patient is diagnosed with acute or chronic GVHD.

12. Other severe disease that may restrain patients from participating in this study (e.g. diabetes, severe cardiac dysfunction, myocardial infarction or unstable arrhythmias or unstable angina in recent 6 months, gastric ulcer, active autoimmune disease, etc.).

Study Design


Related Conditions & MeSH terms


Intervention

Genetic:
CAR-CD19 T cell
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-BCMA T cell
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-GPC3 T cell
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
CAR-CLD18 T cell
Self-controlled dose escalation and classic "3+3" dose escalation will be applied.
Drug:
Fludarabine
Fludarabine is used for lymphodepletion.
Cyclophosphamide
Cyclophosphamide is used for lymphodepletion.

Locations

Country Name City State
China First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang

Sponsors (2)

Lead Sponsor Collaborator
Kang YU Carsgen Therapeutics, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Progression-free Survival (PFS) Determine anti-tumor responses to CAR T cell infusion by the length of time during and after the treatment of the malignancy that the patient lives with the disease but it does not get worse. 5 years for BCMA, 2 years for GPC3, CD19 and Claudin 18.2
Other Time to Tumor Progression (TTP) Determine anti-tumor responses to CAR T cell infusion by time to tumor progression. 5 years for BCMA, 2 years for GPC3, CD19 and Claudin 18.2
Other Disease Control Rate (DCR) Determine anti-tumor responses to CAR T cell infusion by proportion of patients who demonstrate response to treatment. 2 years
Other Objective Remission Rate (ORR) Determine anti-tumor responses to CAR T cell infusion by percentage of patients who have achieved complete response or partial response. 2 years
Other Overall survival (OS) Determine anti-tumor responses to CAR T cell infusion by time from study enrollment until death. 5 years for BCMA, 2 years for GPC3, CD19 and Claudin 18.2
Other Number of DNA copies of CAR T cells in tissue samples The number of DNA copies of CAR-BCMA T cells in lymph node samples or bone marrow samples at regular intervals through 24 hours following the initial infusion. 2 years
Other Anti-drug antibody Detect positive rate and titer of anti-drug antibody (ADA). 2 years
Other Changes of cell subsets for CAR T cells against T cells Observe the changes of cell subsets for CAR T cells against T cells (Tcm, central memory T lymphocytes; Tem, effector memory T lymphocytes; Treg, regulatory T-lymphocytes). 2 years
Primary Number of participants with CRA T-related adverse events as assessed by CTCAE v4.03 Number of participants with study related adverse events which are defined as laboratory toxicities and clinical events that are possible, likely or definitely related to study treatment at any time from the infusion until week 24, including infusion related toxicity and any toxicity possibly related to CAR T cells. 24 weeks
Secondary Engraftment Duration of in vivo survival of CAR T cells is defined as "engraftment". The primary engraftment endpoint is the number of DNA vector copies per mL blood of CAR T cells at regular intervals through 24 hours following the initial infusion. PCR for CAR T vector sequences will be performed until any 2 sequential tests are negative, documented as engraftment of CAR T cells. 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT04209491 - Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
Completed NCT03963206 - Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE) Phase 4
Completed NCT03268499 - TACE Emulsion Versus Suspension Phase 2
Recruiting NCT05044676 - Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
Recruiting NCT05263830 - Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
Recruiting NCT05095519 - Hepatocellular Carcinoma Imaging Using PSMA PET/CT Phase 2
Recruiting NCT05497531 - Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers N/A
Completed NCT05068193 - A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers Phase 1
Active, not recruiting NCT03781934 - A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Phase 1/Phase 2
Terminated NCT03655613 - APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC Phase 1/Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04242199 - Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors Phase 1
Completed NCT04401800 - Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Phase 2
Withdrawn NCT05418387 - A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona N/A
Active, not recruiting NCT04039607 - A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma Phase 3
Terminated NCT03970616 - A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Phase 1/Phase 2
Recruiting NCT03642561 - Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE Phase 2/Phase 3
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Recruiting NCT06239155 - A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors Phase 1/Phase 2
Completed NCT03222076 - Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer Phase 2